GlassScriptPhysician profile
Araceli Elizalde
NPI 1811174873
$51,098.31
in general payments reported to CMS, 2019-2025
34 companies · $19K in 2025
The $19K reported for 2025 was more than what 91% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $474 · 2021: $1,031 · 2022: $9,092 · 2023: $5,217 · 2024: $16K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $20K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,311 · Food and Beverage: $5,093 · Consulting Fee: $4,452 · Travel and Lodging: $1,304 · Education: $71.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $19,978.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,311.00 |
| Food and Beverage | $5,092.59 |
| Consulting Fee | $4,451.66 |
| Travel and Lodging | $1,303.80 |
| Education | $71.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $19,708.14 | 2023-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $10,698.11 | 2020-2025 | Cuvitru, Hyqvia |
| Sanofi US Services INC. | $9,571.49 | 2025 | |
| Adma Biomanufacturing LLC | $2,235.62 | 2021-2025 | |
| Pharming Healthcare, INC. | $1,721.82 | 2022-2025 | Joenja, Ruconest |
| Regeneron Healthcare Solutions, INC. | $1,216.34 | 2019-2025 | Dupixent |
| Csl Behring | $618.51 | 2019-2025 | Hizentra |
| Glaxosmithkline, LLC. | $607.30 | 2020-2025 | Nucala |
| Sanofi-Aventis U.S. LLC | $605.11 | 2020-2025 | |
| Genzyme Corporation | $501.43 | 2019-2025 | |
| Genentech USA, INC. | $436.42 | 2020-2025 | Xolair |
| Grifols USA, LLC | $396.18 | 2021-2025 | Xembify, Gamunex-C |
| Astrazeneca Pharmaceuticals LP | $381.64 | 2020-2025 | Fasenra, Tezspire, Airsupra |
| Tersera Therapeutics LLC | $370.00 | 2024 | |
| Pfizer INC. | $339.56 | 2020-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $314.86 | 2022-2025 | Cutaquig, Panzyga |
| Horizon Therapeutics Plc | $212.82 | 2019-2023 | Actimmune |
| Kaleo, INC. | $182.87 | 2021-2024 | Auvi-Q |
| Alk-Abello, INC | $164.40 | 2020-2025 | Ragwitek, Odactra, Grastek |
| Amgen INC. | $154.52 | 2022-2025 | Tezspire, Actimmune |
| Ars Pharmaceuticals Operations, INC. | $139.85 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $82.39 | 2025 | |
| Greer Laboratories, INC. | $69.63 | 2024-2025 | Oralair |
| Optinose US, INC. | $64.32 | 2021-2025 | |
| Gc Biopharma USA, INC. | $51.98 | 2025 | Alyglo |
| Hikma Pharmaceuticals USA | $46.56 | 2022-2023 | Kloxxado |
| Organon LLC | $39.50 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $37.30 | 2025 | Nemluvio |
| Leo Pharma INC. | $28.14 | 2025 | Anzupgo |
| Bio Products Laboratory USA, INC. | $27.98 | 2021 | |
| Shire North American Group INC | $25.68 | 2019 | |
| Incyte Corporation | $17.87 | 2021 | |
| Itamar Medical INC | $17.50 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Araceli Elizalde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.